Workday Stock And 2 Growth Picks Backed By Insider Confidence

With central banks weighing their next moves, inflation signals pulling in different directions and energy prices feeding through to consumer bills, many investors are looking for companies that show clear internal conviction about their own prospects. Fast Growing Stocks With High Insider Ownership focus on businesses where management and key shareholders have meaningful capital at stake and where external analysts hold an optimistic outlook. That combination can help investors filter for growth stories that are not only discussed but also backed with personal money. This article highlights 3 stocks from that screener that may warrant closer inspection.

Workday (WDAY)

Overview: Workday is a cloud software company that helps large organisations run core finance, HR, planning and student systems in one place, so teams can manage payroll, expenses, workforce planning and financial reporting through a single platform that is increasingly using AI to automate routine work and surface insights.

Operations: Workday generates all of its US$9.9b in revenue from cloud applications, with around US$7.4b coming from the United States and about US$2.5b from other countries.

Market Cap: US$39.0b

Investors considering growth together with insider conviction may find Workday worth examining. Its AI driven HR and finance products are seeing broad customer adoption, and earnings growth has recently outpaced much of the software sector. Margin expansion and what some investors may view as high quality earnings support this narrative, even though the stock currently trades on a higher P/E and relies on external borrowing rather than customer deposits. Recent partnerships and government certifications also indicate deeper integration in areas such as federal agencies and healthcare. At the same time, competition from large incumbents and newer AI first platforms, along with higher compliance and investment costs, keeps the risk side of the equation significant and worth understanding in more detail.

Workday’s AI driven earnings story looks strong, yet the full picture of quality and momentum sits beneath the headlines. Review the analysis report for Workday to see what might be missing from the surface narrative.

MasTec (MTZ)

Overview: MasTec is an infrastructure engineering and construction company that builds and maintains critical assets such as power lines, renewable energy projects, pipelines, fiber networks, data centers and other utility infrastructure across the United States and Canada.

Market Cap: US$25.7b

MasTec provides direct exposure to some of the largest structural spending themes today, including grid upgrades, renewable energy projects, broadband buildouts and the growing need for data center and AI related power infrastructure. Earnings have grown quickly, supported by a record US$21.4b backlog and the recent acquisition of The Superior Group, which adds more reach into mission critical data centers. At the same time, high debt levels, heavy investment in people and equipment, and reliance on large customers and favorable policy make execution and regulation key pressure points to watch. The recent share price drop after Q2 2026, despite strong revenue and backlog numbers, highlights how closely the market is watching margins and delivery on this growth story.

MasTec’s record US$21.4b backlog and data center exposure suggest potential growth that the recent share price drop does not fully reflect. The real twist sits in the 4 key rewards and 2 important warning signs

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics is a biopharma company that develops drugs that modulate cortisol to treat severe conditions such as Cushing’s syndrome, ovarian cancer, liver disease and certain neurologic disorders, anchored today by its approved product Korlym and a late stage pipeline that includes relacorilant and miricorilant.

Market Cap: US$12.8b

Corcept Therapeutics is attracting attention because it sits at the point where a profitable rare disease business meets a fast expanding oncology and metabolic pipeline. Recent results show record revenue, a higher full year 2026 sales outlook of US$1.1b to US$1.2b and early traction from Lifyorli in platinum resistant ovarian cancer. At the same time, Korlym concentration, pricing pressure, litigation around generics and the need for smooth FDA decisions on relacorilant keep risk firmly on the table. For investors interested in fast growing, founder influenced biopharma with real cash flows, the balance between these growth drivers and risks is where the real story sits.

Corcept Therapeutics sits where a rare disease cash engine meets an expanding cancer and metabolic pipeline, yet the real swing factor lies in the analyst forecasts for Corcept Therapeutics that could reshape how investors view its risk profile

The three stocks in this article are only a starting point, and the full screener has surfaced 167 more fast growing companies with high insider ownership that carry equally compelling growth and insider conviction stories in the Fast Growing Stocks With High Insider Ownership screener. Use Simply Wall St to identify and analyze the specific catalysts, insider signals and growth narratives that match your own highest conviction ideas so you can focus on the opportunities that fit you best.

Take Control of Your Investment Journey

If Corcept Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

New stock stories move fast. Breakout momentum often flies under the radar for now, then gets caught once the crowd piles in. Scan fresh ideas while it matters and look for opportunities early.

• Spot income workhorses early by reviewing 9 dividend fortresses built to keep cash flows coming even when markets feel choppy.
• Hunt for future infrastructure leaders with the 35 power grid technology and infrastructure stocks that highlights companies positioned around grid upgrades and energy resilience.
• Track the backbone of tomorrow’s AI demand using the 8 top copper producer stocks to identify producers linked to long term electrification trends.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com